Humira Biosimilars: Complete 2026 Guide

All FDA-approved adalimumab biosimilars — interchangeability, costs, and how to choose

Key Takeaways

There are 8+ FDA-approved adalimumab biosimilars for Humira as of 2026
Several have received FDA interchangeable designation — can be substituted at the pharmacy
Biosimilar list prices are typically 15–35% lower than Humira's list price
However, Humira's myAbbVie Assist copay program is very strong — insured patients may pay less for Humira than a biosimilar
BiologicHealthPlus compares all options on your plan to find the lowest cost

FDA-Approved Humira (Adalimumab) Biosimilars

Biosimilar Name	Manufacturer	Interchangeable?	Concentration
Hadlima (adalimumab-bwwd)	Samsung Bioepis / Organon	Yes	Citrate-free formulation available
Hyrimoz (adalimumab-adaz)	Sandoz	Yes	Citrate-free high-concentration
Cyltezo (adalimumab-adbm)	Boehringer Ingelheim	Yes — first interchangeable adalimumab	Standard and citrate-free
Abrilada (adalimumab-afzb)	Pfizer	Yes	Citrate-free
Yusimry (adalimumab-aqvh)	Coherus BioSciences	Yes	Citrate-free — significant price discount
Idacio (adalimumab-aacf)	Fresenius Kabi	Yes	Citrate-free
Hulio (adalimumab-fkjp)	Mylan / Viatris	Yes	Standard formulation
Simlandi (adalimumab-ryvk)	Alvotech / Teva	Yes	Citrate-free high-concentration

Humira vs Biosimilar: Which Costs Less for You?

The answer depends entirely on your insurance plan's formulary and which manufacturer savings programs you qualify for. This is counterintuitive but important:

📊 When Humira May Be Cheaper

AbbVie's myAbbVie Assist copay card reduces Humira to $0–$35/month for most commercially insured patients. Some Humira biosimilars have less robust copay programs, making Humira the more affordable option for insured patients.

📊 When a Biosimilar May Be Cheaper

If your insurance plan places Humira on a higher formulary tier but a biosimilar on a lower tier, the biosimilar may cost significantly less. Uninsured patients paying cash may benefit from lower biosimilar list prices.

Most FDA-approved Humira biosimilars are approved for all or most of the same indications as Humira (adalimumab), including rheumatoid arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, and uveitis. The specific approved indications vary slightly by biosimilar — BiologicHealthPlus will confirm your specific biosimilar covers your diagnosed condition.

FDA-approved adalimumab biosimilars have demonstrated no clinically meaningful differences in efficacy and safety compared to Humira. Multiple switching studies and real-world evidence support that stable patients can transition to interchangeable biosimilars without loss of disease control. Your prescribing physician will advise on whether switching is appropriate for your situation.

In most cases, yes — switching to a biosimilar requires a new prior authorization even if you already have an approved PA for Humira. BiologicHealthPlus handles the entire biosimilar PA process at no charge and will coordinate with your prescriber to ensure a smooth transition without treatment gaps.

✅ BiologicHealthPlus Finds Your Lowest-Cost Option

We compare Humira and all available adalimumab biosimilars on your specific insurance plan to identify the lowest out-of-pocket cost — then handle all prior authorization and enrollment.

Compare Humira vs Biosimilar →

📚 Sources & Further Reading

Content developed with reference to leading health organizations, peer-reviewed research, and FDA prescribing information.

🔗

Adalimumab BiosimilarsFDA

🔗

AdalimumabWikipedia

🔗

Adalimumab Biosimilar ReviewNIH/NCBI

🔗

ACR on BiosimilarsACR

Medical Disclaimer: Educational content reviewed by the BiologicHealthPlus Clinical Team. Consult your healthcare provider for personalized advice. Last reviewed: August 2026.

FDA approval status and biosimilar interchangeability designations are subject to change. Information current as of July 2026.